メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
光学医療診療部
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(1)
研究成果
(22)
データセット
(4)
フィンガープリント
光学医療診療部が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Advanced Gastric Cancer
84%
Cisplatin
60%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
53%
Gastrointestinal Stromal Tumor
50%
Docetaxel
50%
Gastric Cancer
42%
Endoscopic Submucosal Dissection
42%
Fluoropyrimidine
35%
Helicobacter Pylori (H. pylori)
35%
Shakuyakukanzoto
33%
Intra-aortic Balloon Occlusion
33%
Endoscopic Hemostasis
33%
Endoscopic Retrograde Cholangiopancreatography
33%
Jejunum
33%
Stomach
33%
Franseen Needle
33%
Infliximab
33%
Ulcer
33%
Ulcerative Colitis
33%
Median Progression-free Survival
33%
Irinotecan
32%
Chemotherapy
32%
Proton Pump Inhibitors
30%
Japan
29%
Median Overall Survival
28%
Clinical Trials
27%
Risk Factors
27%
Colorectal Cancer
27%
Diarrhea
26%
Older Men
25%
Chemotherapy-induced Diarrhea
25%
Monotherapy
25%
Amrubicin
25%
Combination Chemotherapy
24%
Inflammatory Bowel Disease
24%
Biopsy Specimen
23%
Endoscopy
22%
Pathological Diagnosis
22%
Paclitaxel
22%
Tumor
21%
KIT Gene
21%
Pancreatitis
21%
Blood Pressure
21%
Stenosis
21%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
21%
Submucosal Tumor
21%
Acute Pancreatitis
20%
Gastrointestinal Cancer
20%
Gastrointestinal Endoscopy
20%
Warfarin
19%
Phase II Study
19%
Neuroendocrine Carcinoma
19%
Intestinal mucosal Injury
18%
S-1 Plus Cisplatin
18%
Randomized Controlled Trial
18%
Treatment Outcome
18%
Drug Use
18%
5-fluorouracil (5-FU)
17%
Second-line Chemotherapy
17%
Confidence Interval
17%
TJ-68
16%
PDGFRA mutation
16%
Interstitial Cells of Cajal
16%
Atypical Manifestations
16%
Gancao
16%
Non-randomized Comparison
16%
Endoscopic Ultrasound Guided Biopsy
16%
Biopsy Needle
16%
Stag Beetle Knife
16%
Superficial Esophageal Neoplasm
16%
IgA Vasculitis (IgAV)
16%
USE Questionnaire
16%
Drug Users
16%
Interstitial Lung Disease
16%
Resectable Pancreatic Cancer
16%
Total Gastrectomy
16%
IgM Antibody
16%
Endoscopic Papillectomy
16%
19-gauge
16%
Gastric Neuroendocrine Carcinoma
16%
Recurrent Lesions
16%
Pulmonary Involvement
16%
Weekly Paclitaxel
16%
Non-invasive Method
16%
Extraintestinal Manifestations
16%
Adult-onset Type II Citrullinemia
16%
Hospital Meals
16%
Constipation
16%
CTLN2
16%
Infectious Mononucleosis
16%
Docetaxel Chemotherapy
16%
Protein-losing Enteropathy
16%
Lupus Erythematosus
16%
Antithrombotic Drugs
16%
Heparin Bridging Therapy
16%
National Database
16%
Amoxicillin
16%
Colonoscopic Polypectomy
16%
Lafutidine
16%
Triple Therapy
16%
Medicine and Dentistry
Abdominal Cancer
55%
Neoplasm
51%
Bleeding
49%
Endoscopic Ultrasound Guided Fine Needle Biopsy
47%
Endoscopic Submucosal Dissection
42%
Ulcer
40%
Endoscopy
39%
Diagnosis
36%
Arm
33%
Jejunum
33%
Endoscopic Ultrasound
33%
Fine-Needle Aspiration
33%
Gastrointestinal Stromal Tumor
33%
Endoscopic Retrograde Cholangiopancreatography
33%
Balloon Occlusion
33%
Endoscopic Hemostasis
33%
Randomized Controlled Trial
33%
Ulcerative Colitis
33%
Biopsy Technique
29%
Pancreas Cancer
28%
Chemotherapy
27%
Duodenum
22%
Retrospective Study
21%
Stenosis
21%
Blood Pressure
21%
Immunity
20%
Nonsteroid Antiinflammatory Agent
20%
Helicobacter Pylori
20%
Warfarin
19%
Fluoropyrimidine
19%
Gastrointestinal Endoscopy
19%
Irinotecan
18%
Antithrombotic
18%
Drug Use
18%
Total Stomach Resection
16%
Clinical Trial
16%
Nivolumab
16%
Cancer Recurrence
16%
Endoscopic Papillotomy
16%
Esophagus Tumor
16%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
16%
Non Invasive Procedure
16%
Duodenum Motility
16%
Non Erosive Reflux Disease
16%
Mitomycin
16%
Duodenal Ulcer Bleeding
16%
Pancreatitis
16%
Interstitial Lung Disease
16%
Self-Expandable Metallic Stent
16%
Reflux Esophagitis
16%
Immunoglobulin M Antibody
16%
Citrullinemia Type II
16%
Infectious Mononucleosis
16%
Protein Losing Enteropathy
16%
Cytomegalovirus
16%
Glycyrrhiza Uralensis Root
16%
Pancreas Carcinoma
16%
Duodenum Stenosis
16%
DNA Mismatch Repair
16%
Antibody Response
16%
Colon Ulcer
16%
Down Syndrome
16%
Gastrointestinal Disease
16%
Transitional Cell Carcinoma
16%
Heparin
16%
Intestine Injury
16%
Polypectomy
16%
Proton-Pump Inhibitor
16%
Gastrointestinal Tumor
16%
Lupus Vulgaris
16%
Antihypertensive
16%
Constipation
16%
Infliximab
16%
Vanilloid Receptor 4
16%
Computer Assisted Tomography
15%
Overall Survival
15%
Progression Free Survival
15%
Colorectal Carcinoma
14%
Adverse Event
14%
Salivation
14%
Omeprazole
14%
Diarrhea
14%
Proctocolectomy
13%
Laxative
13%
Hemorrhagic Shock
12%
Oral Drug Administration
12%
Capsule Endoscopy
11%
Pyoderma gangrenosum
11%
Pulmonary Infiltrate
11%
Mental Capacity
11%
Prednisolone
11%
Lung
11%
Koji
11%
Drug Therapy
10%
Methylation
10%
Cisplatin
10%
Epstein Barr Virus
10%
Vasodilator Agent
10%
Magnesium
10%
Recurrent Disease
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Abdominal Cancer
88%
Cisplatin
57%
Docetaxel
50%
Diarrhea
39%
Overall Survival
36%
Fluoropyrimidine
36%
Progression Free Survival
34%
Paclitaxel
33%
Neuroendocrine Carcinoma
33%
Infliximab
33%
Clinical Trial
27%
Irinotecan
26%
Inflammatory Bowel Disease
24%
Acute Pancreatitis
21%
Constipation
21%
Adverse Event
20%
Monotherapy
20%
Amrubicin
20%
Pancreatitis
19%
Fluorouracil
19%
Injury
19%
Crohn's Disease
16%
Mitomycin
16%
Immunoglobulin A
16%
Stag
16%
Mercaptopurine
16%
Tumor Necrosis Factor Inhibitor
16%
Digestive System Cancer
16%
Vasculitis
16%
Pancreas Cancer
16%
Citrullinemia Type II
16%
Esophageal Squamous Cell Carcinoma
16%
Protein Losing Gastroenteropathy
16%
Down Syndrome
16%
Lafutidine
16%
Rabeprazole
16%
Amoxicillin
16%
Helicobacter Pylori
16%
Esophagus Tumor
16%
Nedaplatin
16%
Anticoagulant Agent
16%
Metronidazole
16%
Cytokine
16%
Carcinogenesis
16%
Ramucirumab
16%
Lupus Vulgaris
16%
Koji
16%
Antihypertensive
16%
Ulcerative Colitis
16%
Jaundice
14%
Proton Pump Inhibitor
14%
Adalimumab
13%
Laxative
13%
Combination Therapy
12%
Second-Line Chemotherapy
12%
Gemcitabine
11%
Esophagus Cancer
10%
Immune Checkpoint Inhibitor
10%
Vasodilator Agent
10%
Anemia
9%
Neutropenia
9%
Maximum Tolerated Dose
9%
Capecitabine Plus Oxaliplatin
8%
Liver Metastasis
8%
Rikkunshito
8%
Chemotherapy Induced Nausea and Vomiting
8%
Syndrome
8%
Small Cell Carcinoma
8%
Mitogen Activated Protein Kinase Kinase Inhibitor
8%
Retina Detachment
8%
Citrulline
8%
Hyperammonemia
8%
Vasopressin
8%
Kanamycin
8%
Flapping Tremor
8%
Lactulose
8%
Hepatic Encephalopathy
8%
Branched Chain Amino Acid
8%
Colorectal Carcinoma
8%
Asthma
8%
Amino Acid
8%
Metabolic Disorder
8%
Diseases
8%
Normal Human
8%
Irritable Colon
8%
Dysphagia
8%
Autoimmune Disease
7%
First-Line Chemotherapy
7%
Purpura
6%
Binimetinib
6%
Oteracil Potassium
5%
Ascites
5%
Tegafur
5%
Gimeracil
5%
Mouse Model
5%
Remission
5%
Human Serum Albumin
5%
Collagen Disease
5%
Complement Component C3
5%